Literature DB >> 26837274

Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.

Young Woo Chang1, Hwan Soo Kim1, Seung Pil Jung1, Hoon Yub Kim1, Jae Bok Lee1, Jeoung Won Bae1, Gil Soo Son2,3.   

Abstract

BACKGROUND: Papillary thyroid carcinomas (PTC) with lymph node metastases have a high recurrence rate. We analyzed the potential of lymph node ratio (LNR) and the level of pre-ablation stimulated thyroglobulin (sTg) as risk factors predicting recurrence in patients with pathological N1a PTC.
MATERIALS AND METHODS: This study involved 192 patients with pathologically confirmed PTC and central neck lymph node metastases who underwent total thyroidectomy with central lymph node dissection (CLND). The clinico-pathological characteristics, the pre-ablation sTg level and post-treatment recurrences were examined. Univariate and multivariate analyses were performed to identify factors associated with recurrence in these patients.
RESULTS: During a median follow-up of 63 months, 17 patients had loco-regional recurrences. Receiver operating characteristic curve analysis showed that the appropriate cut-off values for LNR and the pre-ablation sTg level was 0.48 and 9.3 ng/mL, respectively. Patients with LNR values of ≥0.48 had a significantly worse disease-free survival (DFS) than those with LNR values of <0.48 (P = 0.015), and patients with pre-ablation sTg level values of ≥9.3 ng/mL had significantly worse DFS than those with pre-ablation sTg level values <9.3 ng/mL (P < 0.001). Relative to patients with LNR values of <0.48, those with LNR values of ≥0.48 had higher median pre-ablation sTg level values (0.55 vs. 4.20; P < 0.001). The correlation covariant between the LNR value and the pre-ablation sTg level value was r = 0.454 (P < 0.001). Multivariate analysis showed that a LNR value of ≥0.48 (P = 0.386) was not an independent risk factor for recurrence. To the contrary, a pre-ablation sTg level value of ≥9.3 ng/mL (P < 0.001) was an independent risk factor for recurrence.
CONCLUSION: A high pre-ablation sTg level is a better predictor of recurrence in pathological N1a PTC than a high LNR value. Careful follow-up of patients with this risk factor is recommended.

Entities:  

Keywords:  Lymph node ratio; Papillary thyroid carcinoma; Thyroglobulin

Mesh:

Substances:

Year:  2016        PMID: 26837274     DOI: 10.1007/s10147-016-0956-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  22 in total

1.  Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.

Authors:  Julio Ricarte-Filho; Ian Ganly; Michael Rivera; Nora Katabi; Weimin Fu; Ashok Shaha; R Michael Tuttle; James A Fagin; Ronald Ghossein
Journal:  Thyroid       Date:  2012-04-03       Impact factor: 6.568

2.  Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: results in 291 patients with thyroid cancer.

Authors:  M E Girelli; B Busnardo; R Amerio; D Casara; C Betterle; M Piccolo
Journal:  Eur J Nucl Med       Date:  1986

3.  Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer.

Authors:  Kwang Dae Hong; Sun Il Lee; Hong Young Moon
Journal:  J Surg Oncol       Date:  2010-12-22       Impact factor: 3.454

4.  Should central lymph node dissection be considered for all papillary thyroid microcarcinoma?

Authors:  Young Woo Chang; Hwan Soo Kim; Hoon Yub Kim; Jae Bok Lee; Jeoung Won Bae; Gil Soo Son
Journal:  Asian J Surg       Date:  2015-04-22       Impact factor: 2.767

5.  Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer.

Authors:  F Pacini; R Lari; S Mazzeo; L Grasso; D Taddei; A Pinchera
Journal:  Clin Endocrinol (Oxf)       Date:  1985-10       Impact factor: 3.478

6.  Early and late complications after thyroid operations.

Authors:  M H Max; M Scherm; K I Bland
Journal:  South Med J       Date:  1983-08       Impact factor: 0.954

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma.

Authors:  J F Henry; L Gramatica; A Denizot; A Kvachenyuk; M Puccini; T Defechereux
Journal:  Langenbecks Arch Surg       Date:  1998-04       Impact factor: 3.445

9.  Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection.

Authors:  Brian Hung-Hin Lang; Kai Pun Wong; Koon Yat Wan; Chung-Yau Lo
Journal:  Ann Surg Oncol       Date:  2011-10-12       Impact factor: 5.344

10.  Extent of routine central lymph node dissection with small papillary thyroid carcinoma.

Authors:  Yong Sang Lee; Seok Won Kim; Sun Wook Kim; Seok Ki Kim; Han-Sung Kang; Eun Sook Lee; Ki-Wook Chung
Journal:  World J Surg       Date:  2007-10       Impact factor: 3.282

View more
  5 in total

1.  Prognostic Role of Metastatic Lymph Node Ratio in Papillary Thyroid Carcinoma.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Kyungseek Chang
Journal:  J Pathol Transl Med       Date:  2018-08-30

2.  The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: A retrospective cohort study and systematic review of the literature.

Authors:  Evangelos Karvounis; Ioannis Kappas; Anna Angelousi; George-Marios Makris; Thomas D Siamatras; Eva Kassi
Journal:  Oncol Rev       Date:  2021-01-11

3.  Thyroid cancer overdiagnosis and overtreatment: a cross- sectional study at a thyroid cancer referral center in Ecuador.

Authors:  Paola Solis-Pazmino; Jorge Salazar-Vega; Eddy Lincango-Naranjo; Cristhian Garcia; Gabriela Jaramillo Koupermann; Esteban Ortiz-Prado; Tannya Ledesma; Tatiana Rojas; Benjamin Alvarado-Mafla; Cesar Carcamo; Oscar J Ponce; Juan P Brito
Journal:  BMC Cancer       Date:  2021-01-08       Impact factor: 4.430

4.  Significance of micrometastases in the calculation of the lymph node ratio for papillary thyroid cancer.

Authors:  Young Woo Chang; Hwan Soo Kim; Seung Pil Jung; Hoon Yub Kim; Jae Bok Lee; Jeoung Won Bae; Gil Soo Son
Journal:  Ann Surg Treat Res       Date:  2017-02-24       Impact factor: 1.859

5.  The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.

Authors:  Domenico Albano; Francesco Dondi; Valentina Zilioli; Maria Beatrice Panarotto; Alessandro Galani; Carlo Cappelli; Francesco Bertagna; Raffaele Giubbini; Claudio Casella
Journal:  Ann Nucl Med       Date:  2021-06-21       Impact factor: 2.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.